Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids

Although the use of nanotechnology for the delivery of a wide range of medical treatments has potential to reduce adverse effects associated with drug therapy, tissue-specific delivery remains challenging. Here we show that nanoparticles made of grapefruit-derived lipids, which we call grapefruit-derived nanovectors (GNVs), can transport chemotherapeutic agents, siRNA, DNA expression vectors and proteins to different types of cells. We demonstrate the in vivo targeting specificity of GNVs by co-delivering therapeutic agents with folic acid, which in turn leads to significantly increasing targeting efficiency to cells expressing folate receptors. The therapeutic potential of GNVs was further demonstrated by enhancing the chemotherapeutic inhibition of tumor growth in two tumor animal models. GNVs are less toxic than nanoparticles made of synthetic lipids and, when injected intravenously into pregnant mice, do not pass the placental barrier, suggesting they may be a useful tool for drug delivery.

[1]  M. Zöller Tetraspanins: push and pull in suppressing and promoting metastasis , 2009, Nature Reviews Cancer.

[2]  Michael S. Spilman,et al.  Cryo-electron tomography of porcine reproductive and respiratory syndrome virus: organization of the nucleocapsid. , 2009, The Journal of general virology.

[3]  S M Moghimi,et al.  Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. , 2012, Annual review of pharmacology and toxicology.

[4]  R. Haugland,et al.  Coupling of monoclonal antibodies with biotin. , 1995, Methods in molecular biology.

[5]  P. Low,et al.  Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[6]  C. Théry,et al.  Membrane vesicles as conveyors of immune responses , 2009, Nature Reviews Immunology.

[7]  Kinam Park,et al.  Analysis on the current status of targeted drug delivery to tumors. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[8]  Jianping Qi,et al.  Absorption, disposition and pharmacokinetics of solid lipid nanoparticles. , 2012, Current drug metabolism.

[9]  W. Grizzle,et al.  Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells. , 2010, The American journal of pathology.

[10]  R. Manavalan,et al.  Nanotherapeutics to overcome conventional cancer chemotherapy limitations. , 2011, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[11]  W. Grizzle,et al.  Thymus Exosomes-Like Particles Induce Regulatory T Cells1 , 2008, The Journal of Immunology.

[12]  Kenneth A. Dawson,et al.  Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. , 2011, Nature nanotechnology.

[13]  R. Welti,et al.  Overexpression of Arabidopsis Acyl-CoA Binding Protein ACBP3 Promotes Starvation-Induced and Age-Dependent Leaf Senescence[W][OA] , 2010, Plant Cell.

[14]  Yasuo Yoshioka,et al.  Silica and titanium dioxide nanoparticles cause pregnancy complications in mice. , 2011, Nature nanotechnology.

[15]  A. Poliakov,et al.  Adipose Tissue Exosome-Like Vesicles Mediate Activation of Macrophage-Induced Insulin Resistance , 2009, Diabetes.

[16]  Dongmei Sun,et al.  Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  J. Reddy,et al.  Folate-targeted chemotherapy. , 2004, Advanced drug delivery reviews.

[18]  R. N. Saha,et al.  Nanoparticulate drug delivery systems for cancer chemotherapy , 2010, Molecular membrane biology.

[19]  A. Seifalian,et al.  Exosomes as nano-theranostic delivery platforms for gene therapy. , 2013, Advanced drug delivery reviews.

[20]  Erik C. Dreaden,et al.  Size matters: gold nanoparticles in targeted cancer drug delivery. , 2012, Therapeutic delivery.

[21]  Samir Mitragotri,et al.  Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. , 2010, Current pharmaceutical design.

[22]  Eleonore Fröhlich,et al.  The role of nanoparticle size in hemocompatibility. , 2009, Toxicology.

[23]  M. Kislalioglu,et al.  Nanoparticles in the pharmaceutical industry and the use of supercritical fluid technologies for nanoparticle production. , 2012, Current drug delivery.

[24]  G. Robertson,et al.  Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems , 2012, Expert opinion on drug metabolism & toxicology.

[25]  W. Grizzle,et al.  Immature myeloid cells induced by a high‐fat diet contribute to liver inflammation , 2009, Hepatology.

[26]  Yang-hsin Shih,et al.  The effect of inorganic ions on the aggregation kinetics of lab-made TiO2 nanoparticles in water , 2012 .

[27]  S. Rubin,et al.  Human intestinal folate transport: cloning, expression, and distribution of complementary RNA. , 1997, Gastroenterology.

[28]  E Ingham,et al.  Signalling of DNA damage and cytokines across cell barriers exposed to nanoparticles depends on barrier thickness. , 2011, Nature nanotechnology.

[29]  M. Wood,et al.  Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes , 2011, Nature Biotechnology.

[30]  W. Grizzle,et al.  Exosomes are endogenous nanoparticles that can deliver biological information between cells. , 2013, Advanced drug delivery reviews.

[31]  J. James,et al.  Research strategies for safety evaluation of nanomaterials, part IV: risk assessment of nanoparticles. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[32]  J. Benoit,et al.  Passive and active tumour targeting with nanocarriers. , 2011, Current drug discovery technologies.

[33]  J. Belisle,et al.  Isolation of a distinct Mycobacterium tuberculosis mannose-capped lipoarabinomannan isoform responsible for recognition by CD1b-restricted T cells. , 2012, Glycobiology.

[34]  S. W. Kim,et al.  Optimization of factors influencing the transfection efficiency of folate-PEG-folate-graft-polyethylenimine. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[35]  W. Xia,et al.  Sensitive bioassay for detection of PPARα potentially hazardous ligands with gold nanoparticle probe. , 2011, Journal of hazardous materials.

[36]  Dongmei Sun,et al.  A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  A. Jackman,et al.  Exploitation of the folate receptor in the management of cancer and inflammatory disease. , 2008, Vitamins and hormones.

[38]  W. Grizzle,et al.  TLR2-mediated expansion of MDSCs is dependent on the source of tumor exosomes. , 2010, The American journal of pathology.

[39]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.